Skip to main content
HRES 242 116th Congress House

Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development…

Official title: Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continu… Show full official titleShow less

Official title: Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development for rare diseases.

Introduced: January 27, 2020 See on congress.gov
Health Congressional tributesDrug safety, medical device, and laboratory regulationDrug therapyHealth care costs and insurance
More subjectsShow fewer subjects
Health care coverage and accessHealth care qualityHealth promotion and preventive careMedical researchPrescription drugsResearch and development
Sign in to write a letter Sign in to watch
This resolution expired with the 116th Congress
It was not agreed to before the 116th Congress (2019–2020) adjourned, so it is no longer active. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Agreed to (House)
Mar 19, 2019
Referred to the Subcommittee on Health.
Mar 18, 2019
Referred to the House Committee on Energy and Commerce.
Mar 18, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action March 19, 2019

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

This resolution applauds the growth in research and development into new therapies for rare diseases and recognizes that significant research and development efforts and related investments are needed to develop therapies to treat and cure thousands of rare diseases for which no treatment options are currently available.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 6
All 6 Democratic 3 Republican 1
D
Neguse, Joe
Colorado · Jan 27, 2020
Yarmuth, John
· Oct 28, 2019
 D
Bishop, Sanford D.
Georgia · Oct 17, 2019
 D
Lee, Susie
Nevada · Sep 17, 2019
Flores, Bill
· May 1, 2019
 R
Bilirakis, Gus M.
Florida · Mar 18, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). H. Res. 242: Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development for rare diseases.. 116th Congress. Open America. https://openamerica.io/bill/116-HRES-242/
MLA
"H. Res. 242: Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development for rare diseases.." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HRES-242/.
Bluebook (legal)
H. Res. 242, 116th Cong. (2026), https://openamerica.io/bill/116-HRES-242/.
Markdown link
[H. Res. 242: Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development for rare diseases.](https://openamerica.io/bill/116-HRES-242/)
Report a problem